Page 1,874«..1020..1,8731,8741,8751,876..1,8801,890..»

Schoolgirl comment points to antibiotics as new cancer treatments

Posted: January 28, 2015 at 5:50 am

Professor Michael P. Lisanti, Director of the Breakthrough Breast Cancer Unit, led the research. He was inspired to look at the effects of antibiotics on the mitochondria of cancer stem cells by a conversation with his daughter Camilla about his work at the University's Institute of Cancer Sciences.

His new paper, published in Oncotarget, opens up the possibility of a treatment for cancer, which is highly effective and repurposes drugs which have been safely used for decades.

Mitochondria are the 'engine' parts of the cells and are the source of energy for the stem cells as they mutate and divide to cause tumours. Cancer stem cells are strongly associated with the growth and recurrence of all cancers and are especially difficult to eradicate with normal treatment, which also leads to tumours developing resistance to other types of therapy.

Professor Lisanti said: "I was having a conversation with Camilla about how to cure cancer and she asked why don't we just use antibiotics like we do for other illnesses. I knew that antibiotics can affect mitochondria and I've been doing a lot of work recently on how important they are to the growth of tumours, but this conversation helped me to make a direct link."

Professor Lisanti worked with colleagues from The Albert Einstein College of Medicine, New York and the Kimmel Cancer Centre, Philadelphia. The team used five types of antibiotics - including one used to treat acne (doxycycline) - on cell lines of eight different types of tumour and found that four of them eradicated the cancer stem cells in every test. This included glioblastoma, the most aggressive of brain tumours, as well as lung, prostate, ovarian, breast, pancreatic and skin cancer.

Mitochondria are believed to be descended from bacteria which joined with cells early on in the evolution of life. This is why some of the antibiotics which are used to destroy bacteria also affect mitochondria, though not to an extent which is dangerous to people. When they are present in stem cells, mitochondria provide energy for growth and, crucially, for division, and it is this process going wrong which leads to cancer.

In the lab, the antibiotics had no harmful effect on normal cells, and since they are already approved for use in humans, trials of new treatments should be simpler than with new drugs - saving time and money.

Professor Lisanti said: "This research makes a strong case for opening new trials in humans for using antibiotics to fight cancer. Many of the drugs we used were extremely effective, there was little or no damage to normal cells and these antibiotics have been in use for decades and are already approved by the FDA for use in humans. However, of course, further studies are needed to validate their efficacy, especially in combination with more conventional therapies."

Dr Matthew Lam, Senior Research Officer at Breakthrough Breast Cancer, said: "The conclusions that the researchers have drawn, whilst just hypotheses at this stage, are certainly interesting. Antibiotics are cheap and readily available and if in time the link between their use and the eradication of cancer stem cells can be proved, this work may be the first step towards a new avenue for cancer treatment.

"This is a perfect example of why it is so important to continue to invest in scientific research. Sometimes there are answers to some of the biggest questions right in front of us but without ongoing commitment to the search for these answers, we'd never find them."

See original here:
Schoolgirl comment points to antibiotics as new cancer treatments

Posted in Stem Cells | Comments Off on Schoolgirl comment points to antibiotics as new cancer treatments

Obokata may face criminal charges as former colleague alleges she stole stem cells

Posted: January 28, 2015 at 5:49 am

A criminal investigation now seems likely in the STAP stem-cell research debacle after a former Riken researcher filed a criminal complaint against disgraced scientist Haruko Obokata, alleging she stole samples of embryonic stem cells before reporting that she had created her version of stem cells with a novel technique.

Toshihisa Ishikawa, a former senior researcher at the government-affiliated scientific research organization, submitted the complaint to police in Hyogo Prefecture, where Obokata as a Riken researcher conducted her stem-cell research.

The work secured publication in the prestigious science journal Nature and was widely hailed as groundbreaking before allegations of fabrication emerged.

Ishikawa was not immediately available for comment Tuesday, but press reports have carried his account of what he believes happened.

I am convinced the ES cells Ms. Haruko Obokata used to fabricate her STAP cells were those she stole from the research room of Mr. Teruhiko Wakayama, the latest issue of the gossip weekly Friday quoted Ishikawa as saying. Im going to file a criminal complaint against her alleging that she stole the ES cells, because otherwise confidence in Japans science will be entirely lost.

The prefectural police have yet to decide whether to accept Ishikawas complaint.

A Riken spokesman said Ishikawa was acting in his private capacity in submitting the complaint, but that the institute would cooperate if police ask it to.

Noting that the details of the complaint are still not known and that the police may ultimately reject it, a lawyer representing Obokata nevertheless denied that she stole samples of cells.

Just to be sure, there is no fact that Ms. Obokata stole ES cells, nor was she motivated to do so, lawyer Hideo Miki said in a statement Monday. From what I learned through hearsay, the complaint is poorly put together, and it significantly contradicts the facts. . . . I hope to take appropriate action as necessary.

Ishikawa, who retired from the famed institute last March, alleges the Obokata stole ES cells that were created and stored at the Riken laboratory of Teruhiko Wakayama, which she belonged to, some time after April 2011.

Go here to read the rest:
Obokata may face criminal charges as former colleague alleges she stole stem cells

Posted in Stem Cells | Comments Off on Obokata may face criminal charges as former colleague alleges she stole stem cells

Keeping the kraken asleep: Insight into the role of stem cells in leukemia

Posted: January 28, 2015 at 5:49 am

Despite enormous progress in cancer therapy, many patients still relapse because their treatment addresses the symptoms of the disease rather than the cause, the so-called stem cells. Work in the group of Veronika Sexl at the University of Veterinary Medicine, Vienna has given a tantalizing clue to a solution. In the current issue of Blood, the scientists report that the cell-cycle kinase CDK6 is required for activation of the stem cells responsible for causing leukemia.

Hematopoietic stem cells (HSCs) are normally inactive, i.e. quiescent. When new blood cells are needed, for example to replace blood that has been lost, HSCs start to multiply and develop into mature blood cells. If the process is initiated at an inappropriate time, hematopoietic diseases such as leukemia may result and leukemic stem cells may develop. These represent a major challenge to leukemia therapy: they are quiescent and thus protected from elimination by the immune system and from treatment such as chemotherapy. Leukemic stem cells frequently cause relapse in cancer patients, often years or even decades after an apparently successful treatment.

Working with stem cells isolated from mice, Ruth Scheicher and colleagues at the University of Veterinary Medicine, Vienna have investigated possible differences between leukemic stem cells and the healthy stem cells in the body. They looked in particular at the function of the CDK6 protein, which is known to be involved in controlling the cell cycle. Surprisingly, CDK6 was also found to regulate the activation of hematopoietic and leukemic stem cells, which it does by inhibiting the transcription factor Egr1. Upon loss of CDK6, Egr1 becomes active and prevents stem cells from dividing. In a further twist to the tale, the mechanism operates only when hematopoietic stem cells are stressed, e.g. in leukemia, and not in the normal physiological situation.

Scheicher is quick to note the significance of her finding. "CDK6 is absolutely necessary for leukemic stem cells to induce disease but plays no part in normal hematopoiesis. We thus have a novel opportunity to target leukemia at its origin. Inhibiting CDK6 should attack leukemic stem cells while leaving healthy HSCs unaffected."

Story Source:

The above story is based on materials provided by University of Veterinary Medicine -- Vienna. Note: Materials may be edited for content and length.

View original post here:
Keeping the kraken asleep: Insight into the role of stem cells in leukemia

Posted in Stem Cells | Comments Off on Keeping the kraken asleep: Insight into the role of stem cells in leukemia

MediVet Biologics announces an exciting speaking engagement at the Western Veterinary Conference (WVC) lead by …

Posted: January 28, 2015 at 5:49 am

Nicholasville, Kentucky (PRWEB) January 28, 2015

Cancer Vaccines are few and far between, especially when dealing with canine cancers. In fact, there are only a few viable treatment options available to our beloved pets. MediVet Biologics, a leading provider of in-clinic regenerative medicine services is pleased to announce, K9-ACV a canine cancer vaccine and service applicable to the general practice!

This novel technology has generated excitement and many inquiries since the announcement of its development in early 2015. MediVet Biologics will be hosting a lunch and learn at the Western Vet Conference (WVC) on Tuesday February 17th from Noon to 2PM (PST). The two inventors and industry opinion leaders, Drs. John Yanelli and Don Cohen from the University of Kentucky College of Medicine will be presenting the technology protocols and answering questions.

Also, the progressive conversation continues as Dr. Mike Hutchinson, the Worlds leading Veterinary Regenerative Medicine practitioner, will also be sharing some exciting developments in the field of regenerative medicine. With his 850 stem cell therapy procedures, Dr. Mike has seen it all but he continues to be impressed at the life changing effects stem cell therapy has on his patients.

Please join MediVet Biologics on Tuesday, February 17th from Noon to 2PM (PST) in the Palo Verde room at the Four Seasons for this exciting opportunity to learn about cutting edge technologies!

Space is at a premium and very limited, be sure to pre-register to ensure a seat. All pre-registrants receive a free Cancer Service ($750 value) and are entered to win one of two valuable giveaways! MediVet will be drawing for a free MediVet Stem Cell System or full tuition to the University of Tennessees Certificate program in Canine Rehabilitation (CCRP).

Register online, click here

Or

Contact: Jenny Corbin jenny(at)medivetbiologics(dot)com 859.885.7111 ext. 307

About MediVet Biologics MediVet Biologics headquartered just outside Lexington, KY and Sydney Australia is a subsidiary of Medical Australia (MLA: ASX). MediVet Biologics has global reach including established partners in 26 countries around the world as well as strong market positioning in North America. The company provides novel treatment options based in science to the Veterinary market and provides unique customer specific service plans to ensure implementation and growth of its progressive products and services.

Continued here:
MediVet Biologics announces an exciting speaking engagement at the Western Veterinary Conference (WVC) lead by ...

Posted in Regenerative Medicine | Comments Off on MediVet Biologics announces an exciting speaking engagement at the Western Veterinary Conference (WVC) lead by …

Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr.PV Mahajan – Video

Posted: January 28, 2015 at 5:43 am


Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr.PV Mahajan
Patient testimonial of Limb Girdle Muscular Dystrophy treated by StemRx Bioscience Solutions Pvt. Ltd.

By: StemRx BioScience

Originally posted here:
Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr.PV Mahajan - Video

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr.PV Mahajan – Video

Keeping the Kraken asleep

Posted: January 28, 2015 at 5:43 am

IMAGE:CDK6 is needed for leukemic stem cell activation (left). When CDK6 is absent, the LSC remains in a quiescent state and leukemia formation is prohibited (right). view more

Credit: Angelika Berger / Vetmeduni Vienna

Despite enormous progress in cancer therapy, many patients still relapse because their treatment addresses the symptoms of the disease rather than the cause, the so-called stem cells. Work in the group of Veronika Sexl at the University of Veterinary Medicine, Vienna has given a tantalizing clue to a solution. In the current issue of Blood, the scientists report that the cell-cycle kinase CDK6 is required for activation of the stem cells responsible for causing leukemia.

Hematopoietic stem cells (HSCs) are normally inactive, i.e. quiescent. When new blood cells are needed, for example to replace blood that has been lost, HSCs start to multiply and develop into mature blood cells. If the process is initiated at an inappropriate time, hematopoietic diseases such as leukemia may result and leukemic stem cells may develop. These represent a major challenge to leukemia therapy: they are quiescent and thus protected from elimination by the immune system and from treatment such as chemotherapy. Leukemic stem cells frequently cause relapse in cancer patients, often years or even decades after an apparently successful treatment.

Working with stem cells isolated from mice, Ruth Scheicher and colleagues at the University of Veterinary Medicine, Vienna have investigated possible differences between leukemic stem cells and the healthy stem cells in the body. They looked in particular at the function of the CDK6 protein, which is known to be involved in controlling the cell cycle. Surprisingly, CDK6 was also found to regulate the activation of hematopoietic and leukemic stem cells, which it does by inhibiting the transcription factor Egr1. Upon loss of CDK6, Egr1 becomes active and prevents stem cells from dividing. In a further twist to the tale, the mechanism operates only when hematopoietic stem cells are stressed, e.g. in leukemia, and not in the normal physiological situation.

Scheicher is quick to note the significance of her finding. "CDK6 is absolutely necessary for leukemic stem cells to induce disease but plays no part in normal hematopoiesis. We thus have a novel opportunity to target leukemia at its origin. Inhibiting CDK6 should attack leukemic stem cells while leaving healthy HSCs unaffected".

###

Service: The article 'CDK6 as a key regulator of hematopoietic and leukemic stem cell activation' by Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, Schneckenleithner C, Salazar-Roa M, Zchbauer-Mller S, Zuber J, Malumbres M, Kollmann K and Sexl V. was published in the journal Blood. http://www.bloodjournal.org/content/125/1/90.long?sso-checked=true

About the University of Veterinary Medicine, Vienna

The University of Veterinary Medicine, Vienna in Austria is one of the leading academic and research institutions in the field of Veterinary Sciences in Europe. About 1,300 employees and 2,300 students work on the campus in the north of Vienna which also houses five university clinics and various research sites. Outside of Vienna the university operates Teaching and Research Farms. http://www.vetmeduni.ac.at

Read the rest here:
Keeping the Kraken asleep

Posted in Stem Cell Therapy | Comments Off on Keeping the Kraken asleep

Dr. Raj at Beverly Hills Orthopedic Institute Now Offering Stem Cell Procedures for Over Twenty Painful Conditions

Posted: January 28, 2015 at 5:43 am

Beverly Hills, California (PRWEB) January 28, 2015

The top orthopedic doctor in Los Angeles and Beverly Hills, Dr. Raj is now offering stem cell procedures for over twenty painful conditions, with new ones including spinal arthritis and degenerative disc disease. The procedures are performed at Beverly Hills Orthopedic Institute and are excellent for offering pain relief and helping patients avoid potentially risky surgery. Call (310) 247-0466 for more information and scheduling.

Stem Cell Therapy is now mainstream and Dr. Raj has been a pioneer with it for all types of musculoskeletal indications. This includes procedures for degenerative and rheumatoid arthritis, tendonitis, ligament injury, fractures, soft tissue injuries, wound healing and more.

He has performed the procedure on patients who have sports injuries to assist with faster healing and a quicker return to the field, along with those trying to avoid surgery such as a joint replacement or rotator cuff repair. The procedures are outpatient and involve minimal risk to patients.

New indications at Beverly Hills Orthopedic Institute include stem cell therapy for spinal arthritis and degenerative disc disease. These are usually very frustrating conditions, as surgery for them can be a roll of the dice. Dr. George Graf, a Double Board Certified pain management doctor in Los Angeles, offers the procedures of the spine.

The procedures are performed either with bone marrow derived stem cells or amniotic derived. The amniotic derived stem cells are processed at an FDA regulated lab and do not involve any fetal or embryonic cells.

For more information and scheduling, call (310) 247-0466.

Follow this link:
Dr. Raj at Beverly Hills Orthopedic Institute Now Offering Stem Cell Procedures for Over Twenty Painful Conditions

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Dr. Raj at Beverly Hills Orthopedic Institute Now Offering Stem Cell Procedures for Over Twenty Painful Conditions

Bone stem cells shown to regenerate bone and cartilage in adult mice – Video

Posted: January 27, 2015 at 1:43 pm


Bone stem cells shown to regenerate bone and cartilage in adult mice
A stem cell capable of regenerating both bone and cartilage has been identified in bone marrow of mice. Further study could provide greater understanding of ...

By: Columbia University Medical Center

See the article here:
Bone stem cells shown to regenerate bone and cartilage in adult mice - Video

Posted in Stem Cell Videos | Comments Off on Bone stem cells shown to regenerate bone and cartilage in adult mice – Video

NEUROSTEM Action Mechanism – Video

Posted: January 27, 2015 at 1:43 pm


NEUROSTEM Action Mechanism
NEUROSTEM is a drug based on mesenchymal stem cells derived from allogeneic umbilical cord blood that is being developed to treat Alzheimer #39;s type dementia. The drug is currently undergoing...

By: Medipost

Go here to see the original:
NEUROSTEM Action Mechanism - Video

Posted in Stem Cell Videos | Comments Off on NEUROSTEM Action Mechanism – Video

Summary Judgment Granted on Behalf of Local Surgeon Who Performed Innovative Stem Cell Study

Posted: January 27, 2015 at 11:56 am

San Diego, California (PRWEB) January 27, 2015

According to court documents, after developing ovarian cancer, the Plaintiff sued a local plastic surgeon for Fraud, Negligence, and Libel, alleging the surgeon did not adequately inform her of cancer risks associated with undergoing a procedure that harvested her fat cells, treated them with enzymes that segregated stem cells from the tissue, and then re-introduced stem cell-concentrated fat back into the body. She alleged she was fraudulently induced to participate in a dangerous/experimental procedure that had not been approved in the United States by the FDA. She further alleged the physician was financially motivated and provided false information to her health insurer in order to excessively bill her for a knowingly ineffective and unsafe study. (San Diego County Courthouse / 37-2013-00057742-CU-MM-CTL)

The Defendant was represented by Neil Dymott attorneys Jonathan Ehtessabian and Clark Hudson. On summary judgment, the defense argued the plaintiff knew exactly what she was doing by participating in the study. There were several study consent forms, which detailed the experimental nature of the study as well as the associated risks. The Plaintiff overtly requested stem cell-enriched fat after seeing a T.V. special on Suzanne Somers results following the same procedure. Additionally, there was well-documented evidence of extensive pre-operative discussions between the Plaintiff, the surgeon, and various members of his staff. The study observed notable increases in retention of volume and shape in surgeries that utilized stem cell-enriched fat versus conventional fat. The surgeon took all appropriate precautions to ensure he was conducting a legitimate study. There were absolutely no deviations from the standard of care. (San Diego County Courthouse / 37-2013-00057742-CU-MM-CTL)

At the summary judgment hearing, the Court agreed the surgeons progressive study was conducted legally within exemptions carved out by the FDA for autologous stem cell procedures (i.e. only when the donor and recipient of stems is the same person), and the study was appropriately performed under the supervision of an FDA-approved Institutional Review Board (IRB). The Court further agreed the defenses scientific evidence established stem cells from the mesenchymal/ectodermal layer could not possibly differentiate into ovarian tissue, which is derived from a completely unrelated tissue layer. If the plaintiffs fat stem cells were to hypothetically become malignant they would form an adipose type cancer such as lipo-sarcoma, not ovarian cancer. Additionally, there is no biological mechanism by which stem cells could reasonably migrate from the breasts/face to the ovaries/fallopian tubes. Cosmetically, the surgeon was able to achieve an excellent result. The plaintiff's ovarian cancer was completely unrelated to the surgeon's procedure. (San Diego County Courthouse / 37-2013-00057742-CU-MM-CTL)

Clark R. Hudson is a shareholder at Neil Dymott and concentrates his practice on the defense of healthcare professionals and civil litigation. Mr. Hudson may be reached at (619) 238-1712 or chudson(at)neildymott(dot)com.

Jonathan R. Ehtessabian is an associate at Neil Dymott. His areas of practice include civil and business litigation and the defense of medical professionals. For further information, Mr. Ehtessabian can be reached at (619) 238-1712 or jehtessabian(at)neildymott(dot)com.

About Neil, Dymott, Frank, McFall & Trexler APLC Neil, Dymott, Frank, McFall & Trexler APLC was founded in San Diego in 1964 and is a multi-service law firm with offices in San Diego, and throughout Southern California. The firm represents clients in a wide range of industries and specialty areas, including employment law, civil litigation, pharmaceutical and medical products manufacturers, transportation, intellectual property, insurance, medical, accounting and other professional practices.

Neil, Dymott, Frank, McFall & Trexler APLC is a member of the International Society of Primerus Law Firms.

See the article here:
Summary Judgment Granted on Behalf of Local Surgeon Who Performed Innovative Stem Cell Study

Posted in California Stem Cells | Comments Off on Summary Judgment Granted on Behalf of Local Surgeon Who Performed Innovative Stem Cell Study

Page 1,874«..1020..1,8731,8741,8751,876..1,8801,890..»